ARTICLE | Company News

Amgen again lifts 2016 guidance, tops consensus

July 27, 2016 7:00 AM UTC

Amgen Inc. (NASDAQ:AMGN) reported 2Q16 financial results that beat estimates and again raised its full-year guidance. The company reported quarterly revenues of $5.69 billion, up from $5.37 billion in 2Q15 and beating the $5.58 billion consensus estimate. Non-GAAP EPS in the quarter was $2.84, up from $2.57 in 2Q15 and topping the $2.74 consensus.

For the third time this year, Amgen raised its full-year guidance. It now expects 2016 non-GAAP EPS of $11.10-$11.40 on revenues of $22.5-$22.8 billion. In April, the company guided to non-GAAP EPS of $10.85-$11.20 on revenues of $22.2-$22.6 billion (see BioCentury Extra, April 28). ...